In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

The FDA recently announced that Novo Nordisk’s semaglutide GLP-1 medication (Ozempic and Wegovy) is no longer in short supply ...

A rapid experimental genetic test can help guide the hands of surgeons as they delicately remove tumors from patients with ...

A battle over how to treat childhood obesity is brewing between two groups who each believe their approach has young people’s ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean it's easier to get them. Many employers and ...

New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices reduced INDIANAPOLIS ...

Eli Lilly and Company announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also reduced the ...

Produced by Eli Lilly, this will be an orally administered drug ... worth of ‘pre-launch inventory’. Pills, being both more cost-effective and more appealing to the consumer, are something of a holy ...

“Was anyone else EXTREMELY UNCOMFORTABLE when jane fonda was being interviewed by lilly singh on the sag red carpet just now? it was so awkward and difficult to watch, jane looked like she ...

Eli Lilly is making a bold move with its experimental weight-loss pill, orforglipron, by recording nearly $550 million in “pre-launch inventory” in its financial statements, well ahead of the drug’s ...